Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Click here to view

Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B